You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-cell lymphoma 2 inhibitors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial (BGB-11417)

Not yet recruiting
  • Leukemia
  • +4 more
  • (no location specified)
Jul 27, 2022

Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest Trial in New Hyde Park (Medtronic

Recruiting
  • Atrial Fibrillation
  • +4 more
  • Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
  • New Hyde Park, New York
    Northwell (Northshore University/Long Island Jewish Hospitals)
Dec 1, 2022

B-cell Malignancies Undergoing Treatment With Bruton Tyrosine

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Non-Interventional Study
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Nov 22, 2023

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Selinexor, Flu, CTX)

Recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 3, 2022

r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase

Not yet recruiting
  • B-cell Lymphoma
  • Beijing, Beijing, China
    Deparment of Hematology, Peking University People's Hospital
Aug 9, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Cardiac Arrhythmias in Subjects Treated With BTK Inhibitors

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +5 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 16, 2023

    Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Tampa (Comprehensive Ablative Bridging Irradiation (CABI),

    Recruiting
    • Large B-cell Lymphoma
    • Relapsed Non-Hodgkin Lymphoma
    • Comprehensive Ablative Bridging Irradiation (CABI)
    • Chimeric Antigen Receptor T-Cell Therapy
    • Tampa, Florida
      Moffitt Cancer Center
    Oct 26, 2023

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • +6 more
    • (no location specified)
    Apr 12, 2023

    Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

    Recruiting
    • Multiple Myeloma (MM)
    • +5 more
    • Santander, Cantabria, Spain
    • +4 more
    Jun 19, 2023

    Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

    Recruiting
    • Diffuse Large B Cell Lymphoma，DLBCL
    • PM 8.4 mg/m2
    • PM 11.2 mg/m2
    • Chengdu, Sichuan, China
      West China Hospital Sichuan University
    Jan 15, 2023

    Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

    Recruiting
    • Relapsed or Refractory CD19+ B-cell Lymphoma
    • +2 more
    • TBI-2001
    • +2 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Jul 26, 2023

    Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • +5 more
    • (no location specified)
    Aug 4, 2023

    Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
    • +8 more
    • Biospecimen Collection
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Mar 8, 2023

    B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

    Recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 9, 2022

    Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

    Active, not recruiting
    • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
    • +22 more
    • External Beam Radiation Therapy
    • Orbital Radiation
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 9, 2022

    High-Dose Methotrexate Clearance in Diffuse Large B-Cell

    Recruiting
    • Central Nervous System Lymphoma
    • Diffuse Large B-Cell Lymphoma
    • Non-Interventional Study
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Sep 8, 2023

    Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

    Recruiting
    • Diffuse Large B-cell Lymphoma Recurrent
    • Diffuse Large B Cell Lymphoma Refractory
    • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Oct 12, 2023

    Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive

    Active, not recruiting
    • Aggressive B-Cell Non-Hodgkin Lymphoma
    • fractionated first dose rituximab
    • Geneva, Switzerland
      University Hospital Geneva
    Apr 21, 2023

    Relapsed/Refractory Large B-Cell Lymphoma Trial in Beijing, Hangzhou (Prizloncabtagene autoleucel)

    Recruiting
    • Relapsed/Refractory Large B-Cell Lymphoma
    • Prizloncabtagene autoleucel
    • Beijing, China
    • +1 more
    Mar 24, 2023